Back to results
US 2026/0151318 A1Published application
Oral care composition comprising enzymes
AssigneeNovozymes A/S
InventorsManish Kumar TIWARI, Lorena González PALMÉN, Dorotea Raventos SEGURA, Mette Rose JOERGENSEN
Life of this patent
Estimating the term…
Abstract
The present invention relates to an enzymatic oral care composition comprising a DNase, a mutanase, a beta-glucanase, and at least one oral care ingredient. The invention further relates to the use of said composition as a medicament, use of said composition in treatment of oral disease, methods of treatment comprising administering said composition to a human subject, methods of removing biofilm comprising contacting an object with said composition, and kits of parts comprising said composition.
Claims14
1:
- An enzymatic oral care composition comprising a DNase, a mutanase, a beta-glucanase, and at least one oral care ingredient.
2:
- The oral care composition according to claim 1, wherein the DNase is a polypeptide having DNase activity and a sequence identity of at least 60% to SEQ ID NO:1.
3:
- The oral care composition according to claim 1, wherein the mutanase is selected from the group consisting of:
- a) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 2;
- b) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 4;
- c) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 5;
- d) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 6;
- e) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 7;
- f) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 8;
- g) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 9;
- h) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 10;
- i) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 11;
- j) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 12;
- k) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 13;
- and
- l) a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 14.
23 more elements
4:
- The oral care composition according to claim 1, wherein the beta-glucanase is selected from the group consisting of:
- a) a polypeptide having endo-1,3(4)-β-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 3;
- b) a polypeptide having endo-1,3(4)-β-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 15;
- and
- c) a polypeptide having endo-1,3(4)-β-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 16.
5 more elements
5:
- The oral compositions according to claim 1,
- i) wherein the DNase is a polypeptide having DNase activity and a sequence identity of at least 60% to SEQ ID NO:
- 1;
- ii) wherein the mutanase is a polypeptide having endo-1,3-α-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 2;
- and
- iii) wherein the beta-glucanase is selected from the group consisting of:
- a) a polypeptide having endo-1,3(4)-β-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 3;
- b) a polypeptide having endo-1,3(4)-β-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 15;
- and
- c) a polypeptide having endo-1,3(4)-β-glucanase activity and a sequence identity of at least 60% to the polypeptide of SEQ ID NO:
- 16.
11 more elements
6:
- The oral care composition according to claim 1,
- i) wherein the DNase comprises, consists essentially of, or consists of SEQ ID NO:
- 1;
- ii) wherein the mutanase comprises, consists essentially of, or consists of SEQ ID NO:
- 2;
- and
- iii) wherein the beta-glucanase comprises, consists essentially of, or consists of SEQ ID NO:
- 3 and/or SEQ ID NO:
- 15 or SEQ ID NO:
- 16.
7 more elements
7:
- The oral care composition according to claim 6,
- i) wherein the DNase comprises, consists essentially of, or consists of SEQ ID NO:
- 1;
- ii) wherein the mutanase comprises, consists essentially of, or consists of SEQ ID NO:
- 2;
- and
- iii) wherein the beta-glucanase comprises, consists essentially of, or consists of SEQ ID NO:
- 3.
5 more elements
8:
- The oral care composition according to claim 1, wherein at least one of the DNase, mutanase, and beta-glucanase has on par or improved chemical stability in the presence of at least one oral care ingredient selected from the group consisting of benzoate, EDTA, ethanol, glycerol, phosphate, fluoride, hydrogen peroxide, and mannitol.
9:
- The oral care composition according to claim 8, wherein chemical stability is determined according to Example 1 herein and wherein chemical stability is determined as thermal stability defined by the thermal unfolding transition midpoint (Tm) in the presence of a particular oral care ingredient.
10:
- The oral care compositions according to claim 1, wherein the oral care composition provides improved biofilm prevention compared to Composition B as determined according to Example 2 herein.
11:
- The oral care composition according to claim 1 in the form of an internal oral care composition in the form of a toothpaste or toothpaste tablet, dental cream, mouthwash or mouthwash tablet, mouth rinse, lozenge, pastille, chewing gum, confectionary, or candy.
12:
- The oral care composition according to claim 1 in the form of an external oral care composition in the form of denture cleaning solution, denture cleaning tablet, or denture cleaning powder.
13-14. (canceled)
15:
- A kit of parts comprising:
- a) an oral care composition according to claim 1;
- and
- b) instructions for use.
1 more element